Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz’s Opportunity

Executive Summary

An EU guidance issued earlier this year requiring clinical trials for generic copies of low molecular weight heparins may just have shot the European market opportunity for Momenta and its partner Sandoz, according to Momenta's CFO Rick Shea

You may also be interested in...



FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies

FDA approval of Momenta and Sandoz' generic version of Sanofi-Aventis' Lovenox (enoxaparin) suggests the agency is willing to find a way around requiring clinical efficacy and safety data for future biosimilar approvals

FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies

FDA approval of Momenta and Sandoz' generic version of Sanofi-Aventis' Lovenox (enoxaparin) suggests the agency is willing to find a way around requiring clinical efficacy and safety data for future biosimilar approvals

FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies

Agency's five criteria for determining "sameness" of generic enoxaparin to Sanofi-Aventis's low molecular weight heparin could serve as guideposts for future biosimilar approvals.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS051169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel